Until recent years, Lp(a) has lagged behind other atherogenic lipoproteins in the development of targeted lipid lowering therapies. That is now changing, as Professor Ioanna Gouni-Berthold, University of Cologne, Germany explains.
Educational Partners and Supporters
Novartis has provided with arm’s length sponsorship towards the set-up of the Lp(a) Forum. The content was developed independently by the Forum.
(Founding Partner)